BCTX
BCTX clinical trials: BriaCell Therapeutics Corp.
Every trial on ClinicalTrials.gov where BriaCell Therapeutics Corp. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BCTX on the catalyst calendar · BCTX registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2027Sponsor estimate | NCT06072612Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.BriaCell Therapeutics Corporation · Breast Cancer | BCTXLead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Mar 24, 2026Actual | NCT03328026Combination Study of SV-BR-1-GM With RetifanlimabBriaCell Therapeutics Corporation · Breast Cancer | BCTXLead | Phase 1/Phase 2 | Completed | Locked | Locked | Locked |
| Apr 30, 2025Sponsor estimate | NCT06471673A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerBriaCell Therapeutics Corporation · Breast Cancer | BCTXLead | Phase 1/Phase 2 | Unknown status | Locked | Locked | Locked |
| Nov 22, 2018Actual | NCT03066947SV-BR-1-GM in Metastatic or Locally Recurrent Breast CancerBriaCell Therapeutics Corporation · Breastcancer | BCTXLead | Phase 1/Phase 2 | Completed | Locked | Locked | Locked |
- Primary completion Dec 2027Sponsor estimatePhase 3NCT06072612Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.BriaCell Therapeutics Corporation · Breast CancerRecruitingBCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2026ActualPhase 1/Phase 2NCT03328026Combination Study of SV-BR-1-GM With RetifanlimabBriaCell Therapeutics Corporation · Breast CancerCompletedBCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2025Sponsor estimatePhase 1/Phase 2NCT06471673A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerBriaCell Therapeutics Corporation · Breast CancerUnknown statusBCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2018ActualPhase 1/Phase 2NCT03066947SV-BR-1-GM in Metastatic or Locally Recurrent Breast CancerBriaCell Therapeutics Corporation · BreastcancerCompletedBCTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner